Dr Toni Choueiri discusses a new Phase 2 clinical trial on volitinib in patients with papillary renal cell carcinoma (pRCC)

Dr Toni Choueiri discusses a new Phase 2 clinical trial on volitinib in patients with papillary renal cell carcinoma (pRCC)

EMJ

5 years
2,283 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
At the Thirteenth International Kidney Cancer Symposium, Dr Toni Choueiri (Dana-Farber Cancer Institute and Harvard Medical School, MA) discusses the new AstraZeneca-sponsored Phase 2 clinical trial on the c-Met inhibitor, volitinib, in patients with papillary renal cell carcinoma (pRCC). pRCC is the second most common subtype of renal cell carcinoma and is associated with poor clinical outcomes. Dr Choueiri describes how molecular approaches help direct current research in this field and how inappropriate c-Met activation in cancer cells may be important in pRCC progression. Volitinib is a novel c-Met inhibitor; this Phase 2 trial is an open-label, global and multicentre evaluation of the efficacy and safety of volitinib in patients with pRCC.
Up Next Autoplay
Lymphopenia: How This Affects Clinicians and Treatment Today @CleClinicNews
Lymphopenia: How This Affects Clinicians and Treatment Today @CleClinicNews
Category: Non-Hodgkin Lymphoma
4 Views
Cancer-News 2 days
HORIZON Study #ASH19 @RushMedical
HORIZON Study #ASH19 @RushMedical
Category: Multiple Myeloma
0 Views
ash 2 days
Immune Status, Inflammation Can Predict Mortality @CleClinicNews @CleClinicMD
Immune Status, Inflammation Can Predict Mortality @CleClinicNews @CleClinicMD
Category: Non-Hodgkin Lymphoma
0 Views
Cancer-News 2 days
Phase I Study of Duvelisib in CLL/SLL #ASH19 #ASH @DanaFarber
Phase I Study of Duvelisib in CLL/SLL #ASH19 #ASH @DanaFarber
Category: Chronic Lymphocytic Leukemia
12 Views
ash 2 days
MANIFEST, a Phase 2 Study of CPI-0610 @MountSinaiNYC #ASH #ASH19
MANIFEST, a Phase 2 Study of CPI-0610 @MountSinaiNYC #ASH #ASH19
Category: Other
0 Views
ash 2 days
Phase I Study Evaluating NKTR-255 in MM and NHL #ASH #ASH19 @DanaFarber
Phase I Study Evaluating NKTR-255 in MM and NHL #ASH #ASH19 @DanaFarber
Category: Multiple Myeloma
2 Views
ash 3 days
Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of  Hematology (ASH) 2019 Annual Meeting
Nektar Therapeutics Announces Presentation of New Preclinical Data for its IL-15 Agonist, NKTR-255, at the American Society of Hematology (ASH) 2019 Annual Meeting
Category: Immunotherapy
2 Views
cancernewsupdate 3 days
New PreClinical Data for its IL-15 Agonist, NKTR-255 #ASH19 #ASH
New PreClinical Data for its IL-15 Agonist, NKTR-255 #ASH19 #ASH
Category: Immunotherapy
3 Views
ash 3 days
Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Category: Breast Cancer
2 Views
cancernewsupdate 3 days
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL: How This Affects Clinicians? #ASH19 #ASH
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL: How This Affects Clinicians? #ASH19 #ASH
Category: Chronic Lymphocytic Leukemia
2 Views
ash 3 days